Implementing evidence-based strategies for men with biochemically recurrent and advanced prostate cancer: Consensus recommendations from the US Prostate Cancer Conference 2024

Alan H. Bryce; Neeraj Agarwal; Himisha Beltran; Maha H. Hussain; Oliver Sartor; Neal Shore; Emmanuel S. Antonarakis; Andrew J. Armstrong; Jeremie Calais; Michael A. Carducci; Tanya Barauskas Dorff; Jason A. Efstathiou; Martin Gleave; Leonard G. Gomella; Celestia Higano; Thomas A. Hope; Andrei Iagaru; Alicia K. Morgans; David S. Morris; Michael J. Morris; Daniel P. Petrylak; Robert E. Reiter; Matthew B. Rettig; Charles J. Ryan; Scott B. Sellinger; Daniel E. Spratt; Sandy Srinivas; Scott T. Tagawa; Mary Ellen Taplin; Evan Y. Yu; Tian Zhang; Rana R. McKay; Phillip J. Koo; E. David Crawford

doi:10.1002/cncr.35612

Implementing evidence-based strategies for men with biochemically recurrent and advanced prostate cancer: Consensus recommendations from the US Prostate Cancer Conference 2024

Alan H. Bryce
, Neeraj Agarwal
, Himisha Beltran
, Maha H. Hussain
, Oliver Sartor
, Neal Shore
, Emmanuel S. Antonarakis
, Andrew J. Armstrong
, Jeremie Calais
, Michael A. Carducci
, Tanya Barauskas Dorff
, Jason A. Efstathiou
, Martin Gleave
, Leonard G. Gomella
, Celestia Higano
, Thomas A. Hope
, Andrei Iagaru
, Alicia K. Morgans
, David S. Morris
, Michael J. Morris

Daniel P. Petrylak, Robert E. Reiter, Matthew B. Rettig, Charles J. Ryan, Scott B. Sellinger, Daniel E. Spratt, Sandy Srinivas, Scott T. Tagawa, Mary Ellen Taplin, Evan Y. Yu, Tian Zhang, Rana R. McKay, Phillip J. Koo, E. David Crawford

Medicine - Hematology, Oncology, Transplant

Research output: Contribution to journal › Article › peer-review

9 Scopus citations

Abstract

Current US clinical practice guidelines for advanced prostate cancer management contain recommendations based on high-level evidence from randomized controlled trials; however, these guidelines do not address the nuanced clinical questions that are unanswered by prospective trials but nonetheless encountered in day-to-day practice. To address these practical questions, the 2024 US Prostate Cancer Conference (USPCC 2024) was created to generate US-focused expert clinical decision-making guidance for circumstances in which level 1 evidence is lacking. At the second annual USPCC meeting (USPCC 2024), a multidisciplinary panel of experts convened to discuss ongoing clinical challenges related to 5 topic areas: biochemical recurrence; metastatic, castration-sensitive prostate cancer; poly [ADP-ribose] polymerase inhibitors; prostate-specific membrane antigen radioligand therapy; and metastatic, castration-resistant prostate cancer. Through a modified Delphi process, 34 consensus recommendations were developed and are intended to provide clinicians who manage prostate cancer with guidance related to the implementation of novel treatments and technologies. In this report, the authors review the areas of consensus identified by the USPCC 2024 experts and evaluate ongoing unmet needs regarding translational application of the current clinical evidence.

Original language	English (US)
Article number	e35612
Journal	Cancer
Volume	131
Issue number	1
DOIs	https://doi.org/10.1002/cncr.35612
State	Published - Jan 1 2025

Bibliographical note

Publisher Copyright:
© 2024 The Author(s). Cancer published by Wiley Periodicals LLC on behalf of American Cancer Society.

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

advanced prostate cancer
androgen receptor pathway inhibitors
biochemical recurrence
consensus recommendations
poly(ADP-ribose) polymerase (PARP) inhibitors
radioligand therapy

PubMed: MeSH publication types

Journal Article
Consensus Statement

Publisher link

10.1002/cncr.35612

Find It

Find It at U of M Libraries

Cite this

Bryce, A. H., Agarwal, N., Beltran, H., Hussain, M. H., Sartor, O., Shore, N., Antonarakis, E. S., Armstrong, A. J., Calais, J., Carducci, M. A., Dorff, T. B., Efstathiou, J. A., Gleave, M., Gomella, L. G., Higano, C., Hope, T. A., Iagaru, A., Morgans, A. K., Morris, D. S., ... Crawford, E. D. (2025). Implementing evidence-based strategies for men with biochemically recurrent and advanced prostate cancer: Consensus recommendations from the US Prostate Cancer Conference 2024. Cancer, 131(1), Article e35612. https://doi.org/10.1002/cncr.35612

Bryce, AH, Agarwal, N, Beltran, H, Hussain, MH, Sartor, O, Shore, N, Antonarakis, ES, Armstrong, AJ, Calais, J, Carducci, MA, Dorff, TB, Efstathiou, JA, Gleave, M, Gomella, LG, Higano, C, Hope, TA, Iagaru, A, Morgans, AK, Morris, DS, Morris, MJ, Petrylak, DP, Reiter, RE, Rettig, MB, Ryan, CJ, Sellinger, SB, Spratt, DE, Srinivas, S, Tagawa, ST, Taplin, ME, Yu, EY, Zhang, T, McKay, RR, Koo, PJ & Crawford, ED 2025, 'Implementing evidence-based strategies for men with biochemically recurrent and advanced prostate cancer: Consensus recommendations from the US Prostate Cancer Conference 2024', Cancer, vol. 131, no. 1, e35612. https://doi.org/10.1002/cncr.35612

@article{5d4340122b6a492590e94564620bb94d,

title = "Implementing evidence-based strategies for men with biochemically recurrent and advanced prostate cancer: Consensus recommendations from the US Prostate Cancer Conference 2024",

abstract = "Current US clinical practice guidelines for advanced prostate cancer management contain recommendations based on high-level evidence from randomized controlled trials; however, these guidelines do not address the nuanced clinical questions that are unanswered by prospective trials but nonetheless encountered in day-to-day practice. To address these practical questions, the 2024 US Prostate Cancer Conference (USPCC 2024) was created to generate US-focused expert clinical decision-making guidance for circumstances in which level 1 evidence is lacking. At the second annual USPCC meeting (USPCC 2024), a multidisciplinary panel of experts convened to discuss ongoing clinical challenges related to 5 topic areas: biochemical recurrence; metastatic, castration-sensitive prostate cancer; poly [ADP-ribose] polymerase inhibitors; prostate-specific membrane antigen radioligand therapy; and metastatic, castration-resistant prostate cancer. Through a modified Delphi process, 34 consensus recommendations were developed and are intended to provide clinicians who manage prostate cancer with guidance related to the implementation of novel treatments and technologies. In this report, the authors review the areas of consensus identified by the USPCC 2024 experts and evaluate ongoing unmet needs regarding translational application of the current clinical evidence.",

keywords = "advanced prostate cancer, androgen receptor pathway inhibitors, biochemical recurrence, consensus recommendations, poly(ADP-ribose) polymerase (PARP) inhibitors, radioligand therapy",

author = "Bryce, \{Alan H.\} and Neeraj Agarwal and Himisha Beltran and Hussain, \{Maha H.\} and Oliver Sartor and Neal Shore and Antonarakis, \{Emmanuel S.\} and Armstrong, \{Andrew J.\} and Jeremie Calais and Carducci, \{Michael A.\} and Dorff, \{Tanya Barauskas\} and Efstathiou, \{Jason A.\} and Martin Gleave and Gomella, \{Leonard G.\} and Celestia Higano and Hope, \{Thomas A.\} and Andrei Iagaru and Morgans, \{Alicia K.\} and Morris, \{David S.\} and Morris, \{Michael J.\} and Petrylak, \{Daniel P.\} and Reiter, \{Robert E.\} and Rettig, \{Matthew B.\} and Ryan, \{Charles J.\} and Sellinger, \{Scott B.\} and Spratt, \{Daniel E.\} and Sandy Srinivas and Tagawa, \{Scott T.\} and Taplin, \{Mary Ellen\} and Yu, \{Evan Y.\} and Tian Zhang and McKay, \{Rana R.\} and Koo, \{Phillip J.\} and Crawford, \{E. David\}",

note = "Publisher Copyright: {\textcopyright} 2024 The Author(s). Cancer published by Wiley Periodicals LLC on behalf of American Cancer Society.",

year = "2025",

month = jan,

day = "1",

doi = "10.1002/cncr.35612",

language = "English (US)",

volume = "131",

journal = "Cancer",

issn = "0008-543X",

publisher = "John Wiley and Sons Inc.",

number = "1",

}

TY - JOUR

T1 - Implementing evidence-based strategies for men with biochemically recurrent and advanced prostate cancer

T2 - Consensus recommendations from the US Prostate Cancer Conference 2024

AU - Bryce, Alan H.

AU - Agarwal, Neeraj

AU - Beltran, Himisha

AU - Hussain, Maha H.

AU - Sartor, Oliver

AU - Shore, Neal

AU - Antonarakis, Emmanuel S.

AU - Armstrong, Andrew J.

AU - Calais, Jeremie

AU - Carducci, Michael A.

AU - Dorff, Tanya Barauskas

AU - Efstathiou, Jason A.

AU - Gleave, Martin

AU - Gomella, Leonard G.

AU - Higano, Celestia

AU - Hope, Thomas A.

AU - Iagaru, Andrei

AU - Morgans, Alicia K.

AU - Morris, David S.

AU - Morris, Michael J.

AU - Petrylak, Daniel P.

AU - Reiter, Robert E.

AU - Rettig, Matthew B.

AU - Ryan, Charles J.

AU - Sellinger, Scott B.

AU - Spratt, Daniel E.

AU - Srinivas, Sandy

AU - Tagawa, Scott T.

AU - Taplin, Mary Ellen

AU - Yu, Evan Y.

AU - Zhang, Tian

AU - McKay, Rana R.

AU - Koo, Phillip J.

AU - Crawford, E. David

PY - 2025/1/1

Y1 - 2025/1/1

N2 - Current US clinical practice guidelines for advanced prostate cancer management contain recommendations based on high-level evidence from randomized controlled trials; however, these guidelines do not address the nuanced clinical questions that are unanswered by prospective trials but nonetheless encountered in day-to-day practice. To address these practical questions, the 2024 US Prostate Cancer Conference (USPCC 2024) was created to generate US-focused expert clinical decision-making guidance for circumstances in which level 1 evidence is lacking. At the second annual USPCC meeting (USPCC 2024), a multidisciplinary panel of experts convened to discuss ongoing clinical challenges related to 5 topic areas: biochemical recurrence; metastatic, castration-sensitive prostate cancer; poly [ADP-ribose] polymerase inhibitors; prostate-specific membrane antigen radioligand therapy; and metastatic, castration-resistant prostate cancer. Through a modified Delphi process, 34 consensus recommendations were developed and are intended to provide clinicians who manage prostate cancer with guidance related to the implementation of novel treatments and technologies. In this report, the authors review the areas of consensus identified by the USPCC 2024 experts and evaluate ongoing unmet needs regarding translational application of the current clinical evidence.

AB - Current US clinical practice guidelines for advanced prostate cancer management contain recommendations based on high-level evidence from randomized controlled trials; however, these guidelines do not address the nuanced clinical questions that are unanswered by prospective trials but nonetheless encountered in day-to-day practice. To address these practical questions, the 2024 US Prostate Cancer Conference (USPCC 2024) was created to generate US-focused expert clinical decision-making guidance for circumstances in which level 1 evidence is lacking. At the second annual USPCC meeting (USPCC 2024), a multidisciplinary panel of experts convened to discuss ongoing clinical challenges related to 5 topic areas: biochemical recurrence; metastatic, castration-sensitive prostate cancer; poly [ADP-ribose] polymerase inhibitors; prostate-specific membrane antigen radioligand therapy; and metastatic, castration-resistant prostate cancer. Through a modified Delphi process, 34 consensus recommendations were developed and are intended to provide clinicians who manage prostate cancer with guidance related to the implementation of novel treatments and technologies. In this report, the authors review the areas of consensus identified by the USPCC 2024 experts and evaluate ongoing unmet needs regarding translational application of the current clinical evidence.

KW - advanced prostate cancer

KW - androgen receptor pathway inhibitors

KW - biochemical recurrence

KW - consensus recommendations

KW - poly(ADP-ribose) polymerase (PARP) inhibitors

KW - radioligand therapy

UR - https://www.scopus.com/pages/publications/85210766460

UR - https://www.scopus.com/pages/publications/85210766460#tab=citedBy

U2 - 10.1002/cncr.35612

DO - 10.1002/cncr.35612

M3 - Article

C2 - 39616467

AN - SCOPUS:85210766460

SN - 0008-543X

VL - 131

JO - Cancer

JF - Cancer

IS - 1

M1 - e35612

ER -

Implementing evidence-based strategies for men with biochemically recurrent and advanced prostate cancer: Consensus recommendations from the US Prostate Cancer Conference 2024

Abstract

Bibliographical note

UN SDGs

Keywords

PubMed: MeSH publication types

Publisher link

Find It

Other files and links

Fingerprint

Cite this